title: Mechanical properties of the femur after injection of calcium phosphate cement containing arbekacin sulfate and polylactic acid in a rat model of experimental osteoporosis.
abstract: We developed a calcium phosphate cement containing arbekacin sulfate and polylactic acid (CPC95AP) and examined its effects on bone strength by injecting the CPC95AP into the femoral medullary cavity in model rats with osteoporosis. Favorable cortical bone strength was maintained for more than 6 months when CPC95AP was injected into the femoral cavities. This phenomenon was more significant in the weakened femur of osteoporotic rats. The reasons for the increased bone strength are thought to be that the CPC95AP filling increased the geometric moment of inertia and that the binding of CPC95AP with the bones increased Young's modulus. The most important factor is believed to be the increased Young's modulus. The binding of CPC95AP with the bones after filling the femur cavities compensates for the weak extensional strength of CPC95AP, and provides an opportunity to utilize the compressive strength, which is the advantage of CPC95. CPC95AP has antibiotic properties and biocompatibility, and it increases the mechanical strength of the weakened bone; therefore, it is considered useful in bone filling and stiffening.
authors.affiliation: Department of Orthopaedic Surgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka,Tokyo 181-8611, Japan.
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Tanaka
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ishii
mesh_terms: D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001672:Biocompatible Materials; D001843:Bone Cements / Q000737:chemistry; D002130:Calcium Phosphates / Q000627:therapeutic use*; D003982:Dibekacin / Q000008:administration & dosage* / Q000031:analogs & derivatives; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D005260:Female; D005269:Femur / Q000502:physiology*; D019344:Lactic Acid / Q000008:administration & dosage*; D010024:Osteoporosis / Q000503:physiopathology*; D011091:Polyesters; D011108:Polymers / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013314:Stress, Mechanical
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001672:Biocompatible Materials; D001843:Bone Cements; D002130:Calcium Phosphates; D011091:Polyesters; D011108:Polymers; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; D019344:Lactic Acid; C033616:poly(lactide); D003982:Dibekacin; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C031986:arbekacin; C485829:calcium phosphate, dibasic, anhydrous